| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Antiviral agent 81 (4f) effectively inhibited SARS-CoV-2 in VeroE6-eGFP cells with an EC50 of 0.0862 μM, a CC50 of 15.6 μM, and a selectivity index of 181.0[1]. Antiviral agent 81 inhibited HCoV-OC43 (EC50=0.90 μM) and HCoV-229E (EC50=0.21 μM) in HEL299 cells, and YFV (EC50=5.1 μM) and ZIKV (EC50=4.1 μM) in U87 cells, with a CC50 of 20.5 μM in U87 cells[1]. Antiviral drug 81 (10 μM; 10 min) can inhibit CYP2C19, CYP2C9 and CYP3A4 subtypes in human liver microsomes. The inhibition rate of CYP2C19 is the highest, at 36.6%, followed by CYP2C9 at 29.9% and CYP3A4 at 23.8% [1]. Antiviral drug 81 (100 μM; 0, 10, 30, 60, 120, 240 min) has an in vitro plasma half-life of more than 8 hours in human heparinized plasma. After incubation at 37 °C for 4 hours, its retention rate is about 70% [1].
|
|---|---|
| ln Vivo |
Antiviral drug 81 (4f) (2 mg/kg; tail vein injection; single dose; 24 hours after administration) was rapidly metabolized to the active metabolite GS-441524 in a male Sprague-Dawley rat model, with a Cmax of 95.2 ng/mL, a Tmax of 0.500 hours, a T1/2 of 1.60 hours, and an AUC0-last of 248 ng·h/mL[1]. Antiviral drug 81 (10 mg/kg; oral; single dose; 24 hours after administration) was metabolized to the active metabolite GS-441524 in a male Sprague-Dawley rat model, with a Cmax of 136 ng/mL, a Tmax of 1.67 hours, a T1/2 of 2.01 hours, and an AUC0-last of 558 ng·h/mL, and an oral bioavailability of 45.3%[1].
|
| References |
| Molecular Formula |
C32H41N6O9P
|
|---|---|
| Molecular Weight |
684.68
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O[C@@H]1[C@H](O)[C@@H](CO[P@@](N[C@@H](C)C(OCC(CC)CC)=O)(OC2=CC=CC=C2)=O)O[C@]1(C3=CC=C4C(NC(C5CCC5)=O)=NC=NN43)C#N
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4605 mL | 7.3027 mL | 14.6054 mL | |
| 5 mM | 0.2921 mL | 1.4605 mL | 2.9211 mL | |
| 10 mM | 0.1461 mL | 0.7303 mL | 1.4605 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
